Literature DB >> 17639094

Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation.

J Sanchis1, X Bosch, V Bodí, N Bellera, J Núñez, B Benito, J Ordóñez, L Consuegra, M Heras, A Llècer.   

Abstract

OBJECTIVE: To investigate the combination of clinical data, exercise testing and biomarkers for the evaluation of patients with chest pain without ST-segment deviation or troponin elevation.
DESIGN: Prospective cohort design. SETTTING: Two teaching hospitals in Spain. PATIENTS: 422 patients presenting to the emergency department were studied. Leukocyte count, C-reactive protein (CRP), pregnancy-associated plasma protein A (PAPP-A) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were determined. A validated clinical risk score (number of points according to pain characteristics and risk factors) was used for clinical evaluation and early exercise testing was performed. MAIN OUTCOME MEASURES: Adverse events (death, myocardial infarction or revascularisation) during a median 60 weeks follow-up.
RESULTS: By receiver operating characteristic curve analysis, the association between death or myocardial infarction and adverse events was not significant with leukocyte count (p = 0.3, p = 0.3) or CRP (p = 0.5, p = 0.8), was borderline significant with PAPP-A (p = 0.07, p = 0.04) and strongly significant with NT-pro-BNP (p = 0.0001, p = 0.0001). By Cox regression including clinical risk score, exercise testing result and biomarkers, exercise testing was the independent predictor of revascularisation (p = 0.0001), whereas risk score (p = 0.03) and NT-proBNP (p = 0.0004) predicted death or myocardial infarction. The inclusion of NT-proBNP improved the accuracy of the model for death or myocardial infarction (C-statistic 0.84 versus 0.76, p = 0.01). The combination of clinical score and NT-proBNP afforded the stratification in high (17.2%, p = 0.0001), intermediate (5.3%) and low (1.1%) risk categories of death or myocardial infarction.
CONCLUSIONS: NT-proBNP provides incremental prognostic information above that given by clinical history and exercise testing in patients with chest pain without ST-segment deviation and negative troponin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639094     DOI: 10.1136/hrt.2007.115626

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  3 in total

1.  Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease.

Authors:  Boris Bigalke; Konstantinos Stellos; Tobias Geisler; Stephan Lindemann; Andreas E May; Meinrad Gawaz
Journal:  Clin Res Cardiol       Date:  2010-01-05       Impact factor: 5.460

2.  Efficacy of coronary revascularization in patients with acute chest pain managed in a chest pain unit.

Authors:  Juan Sanchis; Vicent Bodí; Julio Núñez; Luis Mainar; Eduardo Núñez; Pilar Merlos; Eva Rúmiz; Gema Miñana; Xavier Bosch; Angel Llácer
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

3.  Plasma B-type natriuretic peptide levels are poorly related to the occurrence of ischemia or ventricular arrhythmias during symptom-limited exercise in low-risk patients.

Authors:  Andreu Porta; José A Barrabés; Jaume Candell-Riera; Luis Agulló; Santiago Aguadé-Bruix; Gustavo de León; Jaume Figueras; David Garcia-Dorado
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.